AbbVie: Pharma Giant Navigating Humira's Decline

Is AbbVie a buy? This pharma giant is navigating Humira biosimilar competition and Juvederm slowdowns, but recent earnings beat expectations, and analysts predict slight upside. Find out if AbbVie's pipeline and financial strength make it a worthwhile investment despite looming challenges. Hosted on Acast. See acast.com/privacy for more information.